Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 128, Issue 2, 2011, Pages 447-456

  Razis, E ^a   Bobos, M ^b   Kotoula, V ^b   Eleftheraki, A G ^c   Kalofonos, H P ^d   Pavlakis, K ^e   Papakostas, P ^f   Aravantinos, G ^g   Rigakos, G ^a   Efstratiou, I ^h   Petraki, K ⁱ   Bafaloukos, D ⁱ   Kostopoulos, I ^b   Pectasides, D ^j   Kalogeras, K T ^b,c   Skarlos, D ⁱ   Fountzilas, G ^b  

^a HYGEIA HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Hellenic Cooperative Oncology Group   (Greece)

^d UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^e Department of Pathology   (Greece)

^f HIPPOKRATION HOSPITAL   (Greece)

^g AGII ANARGIRI CANCER HOSPITAL   (Greece)

^h PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

ⁱ METROPOLITAN HOSPITAL   (Greece)

^j NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

more..

Author keywords

Breast cancer; HER2; PIK3CA; Predictive; PTEN; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEMCITABINE; KI 67 ANTIGEN; LAPATINIB; NAVELBINE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM COMPLEX; PROGESTERONE RECEPTOR; PROTEIN KINASE B; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; GENE; GENE LOSS; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; PIK3CA GENE; PRIORITY JOURNAL; PTEN GENE; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE PROGRESSION; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 79959733118     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1572-5     Document Type: Article

References (24)

1. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 4785 177 182 3798106 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D (Pubitemid 17231334)
2. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 11 783 792 10.1056/NEJM200103153441101 11248153 10.1056/NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D (Pubitemid 32222155)
3. CL Vogel MA Cobleigh D Tripathy JC Gutheil LN Harris L Fehrenbacher DJ Slamon M Murphy WF Novotny M Burchmore S Shak SJ Stewart M Press 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 3 719 726 11821453 10.1200/JCO.20.3.719 1:CAS:528:DC%2BD38XhsVGmt7o%3D (Pubitemid 34111379)
4. M Marty F Cognetti D Maraninchi R Snyder L Mauriac M Tubiana-Hulin S Chan D Grimes A Anton A Lluch J Kennedy K O'Byrne P Conte M Green C Ward K Mayne JM Extra 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 19 4265 4274 10.1200/JCO.2005.04.173 15911866 10.1200/JCO.2005.04.173 1:CAS:528:DC%2BD2MXms12gs70%3D (Pubitemid 46207001)
5. R Nahta D Yu MC Hung GN Hortobagyi FJ Esteva 2006 Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer Nat Clin Pract Oncol 3 5 269 280 10.1038/ncponc0509 16683005 10.1038/ncponc0509 1:CAS:528:DC%2BD28Xltlagtbg%3D (Pubitemid 43731112)
6. K Berns HM Horlings BT Hennessy M Madiredjo EM Hijmans K Beelen SC Linn AM Gonzalez-Angulo K Stemke-Hale M Hauptmann RL Beijersbergen GB Mills MJ van de Vijver R Bernards 2007 A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 4 395 402 10.1016/j.ccr.2007.08.030 17936563 10.1016/j.ccr.2007.08.030 1:CAS:528:DC%2BD2sXht1ais7zL (Pubitemid 47539306)
7. Y Nagata KH Lan X Zhou M Tan FJ Esteva AA Sahin KS Klos P Li BP Monia NT Nguyen GN Hortobagyi MC Hung D Yu 2004 PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 2 117 127 10.1016/j.ccr.2004.06.022 15324695 10.1016/j.ccr.2004.06.022 1:CAS:528:DC%2BD2cXns1arsr8%3D (Pubitemid 39485684)
8. T Fujita H Doihara K Kawasaki D Takabatake H Takahashi K Washio K Tsukuda Y Ogasawara N Shimizu 2006 PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer Br J Cancer 94 2 247 252 10.1038/sj.bjc.6602926 16404430 10.1038/sj.bjc.6602926 1:CAS:528:DC%2BD28XmvVyguw%3D%3D (Pubitemid 43151543)
9. A Fabi G Metro A Di Benedetto C Nistico P Vici E Melucci B Antoniani L Perracchio I Sperduti M Milella F Cognetti M Mottolese 2010 Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies Oncology 78 2 141 149 10.1159/000312656 20389136 10.1159/000312656 1:CAS:528:DC%2BC3cXlsVyjsLs%3D
10. S Gori A Sidoni M Colozza I Ferri MG Mameli D Fenocchio L Stocchi J Foglietta V Ludovini E Minenza V De Angelis L Crino 2009 EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab Ann Oncol 20 4 648 654 10.1093/annonc/mdn681 19188134 10.1093/annonc/mdn681 1:STN:280:DC%2BD1M3jt1Gjsw%3D%3D
11. PP Pandolfi 2004 Breast cancer-loss of PTEN predicts resistance to treatment N Engl J Med 351 22 2337 2338 10.1056/NEJMcibr043143 15564551 10.1056/NEJMcibr043143 1:CAS:528:DC%2BD2cXhtValtrrN (Pubitemid 39552753)
12. LH Saal K Holm M Maurer L Memeo T Su X Wang JS Yu PO Malmstrom M Mansukhani J Enoksson H Hibshoosh A Borg R Parsons 2005 PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma Cancer Res 65 7 2554 2559 10.1158/0008-5472-CAN-04-3913 15805248 10.1158/0008-5472-CAN-04-3913 1:CAS:528:DC%2BD2MXjtVeqsrc%3D (Pubitemid 40490050)
13. LM McShane DG Altman W Sauerbrei SE Taube M Gion GM Clark 2006 REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 100 2 229 235 10.1007/s10549-006-9242-8 16932852 10.1007/s10549-006-9242-8 (Pubitemid 44631925)
14. G Fountzilas M Bobos A Kalogera-Fountzila N Xiros S Murray H Linardou G Karayannopoulou AK Koutras D Bafaloukos E Samantas C Christodoulou T Economopoulos KT Kalogeras P Kosmidis 2008 Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation Cancer Invest 26 8 784 793 10.1080/07357900801918611 18798073 10.1080/07357900801918611 1:CAS:528:DC%2BD1cXht1CqsrnP
15. H Gogas D Pectasides I Kostopoulos E Lianos D Skarlos G Papaxoinis M Bobos HP Kalofonos K Petraki K Pavlakis D Bafaloukos G Fountzilas 2010 Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: a phase II Trial of the Hellenic Cooperative Oncology Group Clin Breast Cancer 10 3 230 237 10.3816/CBC.2010.n.031 20497922 10.3816/CBC.2010.n.031 1:CAS:528:DC%2BC3cXosVSmsrs%3D
16. A Bamias M Karina P Papakostas I Kostopoulos M Bobos G Vourli E Samantas C Christodoulou G Pentheroudakis D Pectasides MA Dimopoulos G Fountzilas 2010 A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer Cancer Chemother Pharmacol 65 6 1009 1021 10.1007/s00280-010-1256-6 20130877 10.1007/s00280-010- 1256-6 1:CAS:528:DC%2BC3cXjtlalsL8%3D
17. J Hugh J Hanson MC Cheang TO Nielsen CM Perou C Dumontet J Reed M Krajewska I Treilleux M Rupin E Magherini J Mackey M Martin C Vogel 2009 Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial J Clin Oncol 27 8 1168 1176 10.1200/JCO.2008.18.1024 19204205 10.1200/JCO.2008.18.1024 1:CAS:528:DC%2BD1MXktFKhs7Y%3D
18. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Allred RJ Cote M Dowsett PL Fitzgibbons WM Hanna A Langer LM McShane S Paik MD Pegram EA Perez MF Press A Rhodes C Sturgeon SE Taube R Tubbs GH Vance M van de Vijver TM Wheeler DF Hayes 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 1 118 145 10.1200/JCO.2006.09.2775 17159189 10.1200/JCO.2006.09.2775 1:CAS:528:DC%2BD2sXht1ejs7Y%3D (Pubitemid 350003059)
19. MC Cheang SK Chia D Voduc D Gao S Leung J Snider M Watson S Davies PS Bernard JS Parker CM Perou MJ Ellis TO Nielsen 2009 Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer J Natl Cancer Inst 101 10 736 750 10.1093/jnci/djp082 19436038 10.1093/jnci/djp082 1:CAS:528: DC%2BD1MXmtlyit74%3D
20. C Christodoulou I Kostopoulos HP Kalofonos E Lianos M Bobos E Briasoulis H Gogas E Razis DV Skarlos G Fountzilas 2009 Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer: phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation Oncology 76 4 275 285 10.1159/000207504 19262067 10.1159/000207504 1:CAS:528:DC%2BD1MXkvVGitrk%3D
21. K Bohmann G Hennig U Rogel C Poremba BM Mueller P Fritz S Stoerkel KL Schaefer 2009 RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods Clin Chem 55 9 1719 1727 10.1373/clinchem.2008.122572 19617290 10.1373/clinchem.2008.122572 1:CAS:528:DC%2BD1MXhtVynt77E
22. G Perez-Tenorio L Alkhori B Olsson MA Waltersson B Nordenskjold LE Rutqvist L Skoog O Stal 2007 PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer Clin Cancer Res 13 12 3577 3584 10.1158/1078-0432.CCR-06-1609 17575221 10.1158/1078-0432.CCR-06-1609 1:CAS:528:DC%2BD2sXmsFCqtbk%3D (Pubitemid 46955118)
23. PR Pohlmann IA Mayer R Mernaugh 2009 Resistance to trastuzumab in breast cancer Clin Cancer Res 15 24 7479 7491 10.1158/1078-0432.CCR-09-0636 20008848 10.1158/1078-0432.CCR-09-0636 1:CAS:528:DC%2BD1MXhsFGgur3F
24. M Kakarala MS Wicha 2008 Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy J Clin Oncol 26 17 2813 2820 10.1200/JCO.2008.16.3931 18539959 10.1200/JCO.2008.16.3931